Imperial College London
Alternate

Professor Nimalan Arinaminpathy (Nim Pathy)

Faculty of Medicine, School of Public Health

Professor in Mathematical Epidemiology
 
 
 
//

Contact

 

nim.pathy Website

 
 
//

Location

 

Praed StreetSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Arinaminpathy:2015:10.2471/BLT.14.147256,
author = {Arinaminpathy, N and Cordier-Lassalle, T and Lunte, K and Dye, C},
doi = {10.2471/BLT.14.147256},
journal = {Bulletin of the World Health Organization},
pages = {237--248},
title = {The Global Drug Facility as an intervention in the market for tuberculosis drugs},
url = {http://dx.doi.org/10.2471/BLT.14.147256},
volume = {93},
year = {2015}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Objective To investigate funding for the Global Drug Facility since 2001 and to analyse the facility’s influence on the price of high-qualitytuberculosis drugs.Methods Data on the price of tuberculosis drugs were obtained from the Global Drug Facility for 2001 to 2012 and, for the private sectorin 15 countries, from IMS Health for 2002 to 2012. Data on funding of the facility were also collected.Findings Quality-assured tuberculosis drugs supplied by the Global Drug Facility were generally priced lower than drugs purchased inthe private sector. In 2012, just three manufacturers accounted for 29.9 million United Stated dollars (US$) of US$ 44.5 million by valueof first-line drugs supplied. The Global Fund to Fight AIDS, Tuberculosis and Malaria provided 73% (US$ 32.5 million of US$ 44.5 million)and 89% (US$ 57.8 million of US $65.2 million) of funds for first- and second-line drugs, respectively. Between 2010 and 2012, the facility’smarket share of second-line tuberculosis drugs increased from 26.1% to 42.9%, while prices decreased by as much as 24% (from US$ 1231to US$ 939). Conversely, the facility’s market share of first-line drugs fell from 37.2% to 19.2% during this time, while prices increased fromUS$ 9.53 to US$ 10.2.Conclusion The price of tuberculosis drugs supplied through the facility was generally less than that on the private market. However, torealize its full potential and meet the needs of more tuberculosis patients, the facility requires more diverse and stable public funding andgreater flexibility to participate in the private market.
AU  - Arinaminpathy,N
AU  - Cordier-Lassalle,T
AU  - Lunte,K
AU  - Dye,C
DO  - 10.2471/BLT.14.147256
EP  - 248
PY  - 2015///
SN  - 1564-0604
SP  - 237
TI  - The Global Drug Facility as an intervention in the market for tuberculosis drugs
T2  - Bulletin of the World Health Organization
UR  - http://dx.doi.org/10.2471/BLT.14.147256
UR  - http://hdl.handle.net/10044/1/39746
VL  - 93
ER  -
Download